Loading...
Helicobacter pylori eradication rates are decreasing as antibiotic resistance increases throughout the world. In a randomized, open-label study involving 114 H. pylori–infected patients in Korea with gastric epithelial neoplasms, investigators compared the efficacy of susceptibility-guided therapy with that of clarithromycin-based triple therapy.
Gastric mucosal biopsy samples were obtained to confirm infection and determine antibiotic-resistance patterns. Half the participants received a proton pump inhibitor (PPI; either 40 mg of lansoprazole or 30 mg of pantoprazole), 1 g of amoxicillin, and 500 mg of clarithromycin, all twice daily for 7 days. The other half received the same PPI and amoxicillin therapy, plus a third drug selected based …